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Background: The development of necrotizing enterocolitis (NEC) in neonates with patent
ductus arteriosus (PDA) is not well-understood. Our aim was to find risk factors for NEC
in children with a significant PDA and to assess differences in mortality and duration of
hospital stay between patients with PDA and those with PDA and NEC.
Methods: We performed a retrospective single center case control study including
infants with PDA scheduled for treatment. We compared multiple patient data between
patients with PDA and those with PDA and NEC from 2004 to 2018 using 1:2 and
1:1 matching.
Results: We used 1:2 matching with 26 NEC patients (cases) and 52 PDA patients
without NEC (controls) and 1:1 matching with 5 NEC patients and 5 PDA patients
without NEC. NEC patients had lower Apgar score (1′), more congenital malformations,
more suspected sepsis, less hypotension, higher minimum platelet count and higher
CRP-values during the week before NEC (P < 0.05, respectively). The mortality was
higher in NEC cases [29% (9/31)] compared to the control patients [2% (1/57), P <
0.001]. Lower Apgar score (1′) was correlated with an increased risk of NEC stage III.
Hypotension was inversely correlated with the odds of NEC (OR 0.3).
Conclusions: NEC increased mortality in infants with PDA. Hypotension did not
increase the risk of NEC in infants with PDA. Routine clinical parameters were not able
to predict NEC in infants who suffer from PDA.
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1. INTRODUCTION
Necrotizing enterocolitis (NEC) affects up to 7% of preterm neonates below 1,500 g of birth weight
(1). Additionally, preterm infants also frequently suffer from patent ductus arteriosus (PDA) (2).
Disturbance of intestinal microcirculation is one of the factors that contributes to necrosis of the
gut in NEC. Accordingly, hypotension has been found to be a risk factor for NEC (3, 4). Since PDA
affects blood flow, it is believed, that hemodynamically relevant PDA might precipitate NEC (2).
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In addition to PDA itself, PDA-related treatment might also
play a role in the pathophysiology of NEC in infants with PDA.
In a metaanalysis by Ohlsson et al. (5) NEC occurred significantly
more often in patients treated for PDA with indomethacin as
compared to infants treated with ibuprofen.
Taken all together, it remains largely unknown—and
impossible to predict—which neonates with PDA will
develop NEC.
Our primary aim was to find risk factors for NEC in children
with a significant PDA. Our secondary aim was to assess
differences in outcomes (duration of hospital stay and mortality)
between the two groups of patients (PDA vs. PDA and NEC).
2. METHODS
We performed a single-center retrospective case-control study
including patients who were born between December 2004 and
June 2018 and treated at the University Children’s Hospital
in Bern, Switzerland. During this period 176 newborns were
diagnosed with NEC in our hospital. Our study was approved
by the local ethics committee (Kantonale Ethikkomission Bern,
Basec-Nr.: 2016-00477).
Our inclusion criteria for cases were defined as development
of NEC (Bell stage ≥ 2) (6) after being diagnosed with PDA.
We only included patients with a PDA who were scheduled
for treatment. On an intention-to-treat basis we also included
patients in whom there was an indication for treatment, however
they never received the treatment (for example due to low platelet
count or other clinical factors). We performed Bell staging based
on a patient chart review, including radiographic imaging. We
included patients with all gestational ages. We excluded infants
with a PDA who were not scheduled for treatment.
For each index case suffering from PDA andNEC, wematched
two controls that each had a PDA without NEC. We used the
following matching criteria: (1) birth weight (BW): if the BW
of the index patient was <1,000 g, we accepted a maximum
difference of 100 g between the index and the control patient; if
the BW was 1,000–1,999 g, we accepted a maximum difference
of 200 g; if the BW was 2,000–2,999 g, we accepted a maximum
difference of 300 g; if the BW was >3,000 g, we accepted a
maximum difference of 500 g. (2) gestational age (GA): We
accepted a maximum difference of 2 weeks. (3) post-natal age at
the time of indication for treatment of the PDA: we accepted a
maximum difference of 5 days.
We extracted the following variables as potential risk factors
for NEC from the patient charts: maternal age, maternal
hypertension or preeclampsia or eclampsia, tocolysis during
pregnancy, prenatal steroids, delivery mode, Apgar scores,
congenital malformations/syndromes, surfactant treatment,
delayed meconium passage, suspected sepsis—as defined by
the presence of three of the following five criteria: elevated
C-Reactive Protein (CRP), leucocytosis or leucopenia (we
used the following reference values for first month of life:
5–25 G/L, later on: 3–15 G/L), elevated count of premature
granulocytes, temperature instability and symptoms of infection
(such as vomiting, diarrhea, irritabilty or neurological changes),
hypotension [defined as a period of mean blood pressure below
GA in weeks (7)], umbilical catheters, cardiac surgery, other
surgery, ventilation (mechanical, Continuous Positive Airway
Pressure), phototherapy, blood transfusion (erythrocytes,
thrombocytes, fresh frozen plasma), drugs (indomethacin,
systemic steroids, erythropoietin, catecholamines, morphine,
antacid agents, immunoglobulins), nutrition (enteral feeding
and parenteral feeding), antibiotic treatment before NEC onset
(days of treatment and name of antibiotic agent), laboratory
findings before NEC onset (umbilical artery/vein pH, minimal
and maximal hemoglobin, minimal and maximal white blood
cell count, minimal platelets, maximal lactate, minimal pH value,
maximal CRP value), mortality, and duration of hospitalization.
In most of these variables we extracted data for the overall time
before NEC onset and the last 7 days before NEC onset. We
extracted laboratory data for the controls in the same time span
as for the cases (e.g., if the case developed NEC at the age of 10
days, we extracted the data up to this age for the case and as well
for the matched controls).
The data were collected in the RedCap database (8) and
analyzed using a combined script written in Perl (9), Python
(10), and R (11). The descriptive analysis was followed by
assessing the statistical differences between both groups. This
was performed using the Wilcoxon signed rank test with
continuity correction for continuous variables and McNemar’s
Chi-squared test for discrete variables. We considered results
as statistically significantly if P was <0.05. Variables which
yielded a statistically significant difference (as indicated in
the Results section) were then analyzed using multi- and
univariate logistic regression (including stepwise regression) for
their influence on development of NEC, development of NEC
stage III, mortality, and duration of hospitalization. For this
purpose, the hospitalization duration was transformed into a
binary variable: long hospital stay (longer than the median
of 86 days or the third quartile of 114 days) and short
hospital stay (shorter than the median or third quartile of the
study population).
Continuous variables are presented as median and 95%
confidence interval (CI95). Discrete variables have been
approximated to binary variables (yes or no) and are presented
as number of positive responses (“yes”) per total number of cases
or controls and the percentage of positive responses. Whenever
data for specific variables were unavailable, this particular case or
control was excluded from the analysis of this variable.
3. RESULTS
In the analysis, we included 31 patients with NEC and PDA and
57 controls with PDA alone. A 1:2 matching on 26 NEC cases
and 52 controls was used, 5 remaining cases were matched 1:1
with 5 controls.
The initial study cohort consisted of 32 cases and 64 controls,
but five of the included controls did not fulfill all of the
matching criteria.
These five patients were included in the primary
analysis, but due to high heterogeneity, they were
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excluded and for their matched cases a 1:1 matching was
conducted. Additionally, in order to further reduce the
heterogeneity, one outlier in terms of gestational age (31
6/7w) was excluded from the NEC group, together with its
corresponding controls.
The following variables differed significantly between the 31
NEC patients and the 57 controls: NEC-patients had significantly
lower gestational age (median, CI95: Cases: 25.3, 23.5–30.4,
Controls: 26.0, 24.1–31.2, P < 0.01, values in the entire cohort
ranged from 23.5 to 31.6), higher birth weight percentile
(median, CI95: Cases: 35, 1.8–84, Controls: 32, 3.4–67, P <
0.001, see Figure 1), lower Apgar score at 1′ (median, CI95:
Cases: 3, 1–7, Controls: 5, 1–8, P < 0.01, see Figure 1), more
malformations [Cases: 7/31 (23%), Controls: 1/57 (2%), P <
0.001, see Figure 2], more often suspected sepsis [Cases: 15/31
(48%), Controls: 12/56 (21%), P < 0.01, see Figure 2], lower
incidence of hypotension [Cases: 10/31 (32%), Controls: 41/57
(72%), P < 0.001, see Figure 2], higher CRP-values during the
week before the development of NEC (median, CI95: Cases: 0,
0–66.6, Controls: 0, 0–10, P < 0.05, see Figure 1) and higher
minimum platelet count during the week before the NEC onset
(median, CI95: Cases: 248, 48.9–580, Controls: 164, 31.8–601, P
< 0.01, see Figure 1).
The malformations/syndromes in the NEC group included:
partial cleft in the maxilla, subglottic stenosis, hypospadia (n
= 2), plagiocephalus, inguinal hernia/hydrocoele testis, Pierre
Robin sequence, and polycystic kidney disease. There was
just one malformation in the control group: Antenatal Bartter
syndrome type 1.
Themortality was higher inNEC cases [29% (9/31)] compared
to the control patients [2% (1/57), P<0.001].
Indomethacin therapy did not differ significantly between the
two groups [Cases: 27/31 (87%), Controls: 50/57 (88%), P = 1].
Likewise, therapy with antibiotics prior to the onset of NEC was
not significantly different [Cases: 29/30 (97%), Controls: 50/56
(89%), P = 0.1]. Catecholamine treatment did not differ between
the two groups either [Cases: 7/29 (24%), Controls: 12/54 (22%),
P = 1].
In the logistic regression assessing NEC risk in PDA patients,
hypotension was inversely (OR 0.31, CI95 0.091–1, P = 0.06)
and suspected sepsis positively (OR 3.6, CI95 1.1–13, P < 0.05)
correlated with the odds of NEC.
A stepwise regression yielded an optimal model for
multivariate regression assessing the risk of NEC in PDA
patients which involved the minimal platelet count one week
before NEC onset (OR 6.1, CI95% 0.01–0.24–1.60–29.96, p-value
< 0.05) and clinically suspected sepsis before onset of the disease
(OR 5.2, CI95% 0.01–0.24–1.60–29.96, p-value < 0.05).
Lower Apgar score at the 1st minute was correlated with an
increased risk of NEC stage III (OR 0.45, CI95 0.18–0.84, P <
0.05)—see Table 1 and Supplementary Tables.
The birth weight percentile correlated with long
hospitalization, but with an OR close to 1 (OR 0.98, CI95
0.94–1, P = 0.1).
None of the parameters significantly affected survival.
All basic cohort data, laboratory parameters and regression
results are shown in Supplementary Tables.
4. DISCUSSION
We found very few clinical parameters that were correlated with
the occurrence of NEC in our cohort of neonates with PDA.
Low Apgar score at 1st minute, high CRP during the week
before NEC onset, high minimum platelet count during the week
before NEC, low prevalence of hypotension, high birth weight
percentile and low gestational age were associated with NEC.
The parameters that were correlated with NEC in the
logistic regression were the absence of hypotension, and higher
minimum platelet count. The correlation between absence of
hypotension and NEC is highly surprising, since, according to
animal studies (12, 13), hypotension may reduce intestinal blood
flow and therefore would favor intestinal necrosis. The fact that
the presence of hypotension did not increase the risk of NEC
might suggest that NEC in infants with PDA might not be
correlated with impaired macrocirculation.
Correlation between suspected sepsis and NEC has already
been described by Rose and Patel (14).
The higher CRP levels during the week preceding NEC onset
as compared to the same post-natal time period in controls
and its influence on the incidence of NEC (P < 0.05) might
suggest a role of increased inflammation in the development of
NEC. To the knowledge of the authors, there is no evidence
for systemic inflammation as an indicator preceeding the onset
of NEC. However, Luo et al. have shown that CRP level is an
indicator of deterioration in NEC in small for gestational age
newborns (15).
We previously described that lower platelet count correlated
with non-survival in surgically treated NEC children (16). Our
present results indicate that higher minimal platelet count
is rather a risk factor for developing NEC. It is difficult to
interpret this finding since no maximal platelet count has
been documented during the study—we therefore think that
speculating about the risk of thrombosis, which has already
been implicated in the pathogenesis of NEC (17), would not
be legitimate.
The lower Apgar scores in the first minute of life correlated
with the development of NEC stage III (see Table 1). One
could hypothesize that a brief post-natal ischemic hit might
have exposed individuals to an increased risk of NEC later on.
However, the Apgar scores at 5 and 10 min were not significantly
different between groups. We therefore can not conclude that
an isolated low Apgar score (1′) reflected a pathophysiologic
phenomenon, but rather an incidental unrelated and not
repeatable finding. Low Apgar score at 1st minute post-partum
has already been proven not to be a valuable prognostic
factor (18).
Blood transfusion rate did not correlate with the incidence
of NEC and did not affect the survival of NEC patients, which
speaks against the hypothesis that red blood cell transfusion
increases the risk of NEC, especially in patients with PDA (19).
However, the absolute number of transfusions in our cohort was
too low to draw definitive conclusions.
Mitra et al. (20) analyzed side effects of treatment of PDA
with Non-Steroidal Inflammatory Drugs (NSAID) and did not
find higher rates of NEC in children with high oral doses of
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FIGURE 1 | (A) Birth weight percentile, P < 0.001, (B) Apgar 1st minute, P < 0.01, (C) maximal CRP < 7 days before NEC onset (mg/l), P < 0.05, (D) minimal
platelet count < 7 days before NEC onset (G/l), P < 0.01.
FIGURE 2 | (A) Malformations, P < 0.001, (B) suspected sepsis, P < 0.01, (C) hypotension, P < 0.001, (D) survival, P < 0.001.
ibuprofen. Consequently, they suggested that the PDA itself
would be a risk for NEC and not the treatment for it. We did
not find any differences in the two groups regarding treatment
with indomethacin or ibuprofen so we cannot support or reject
this statement.
The birth weight percentile and gestational age differed
significantly between groups, but this finding is due to
our imperfect matching criteria which were rather widely
chosen since it was not possible to gather an appropriate
cohort otherwise.
Unfortunately we could not assess enteral feeding (21) as
a widely discussed risk factor in a sufficient way in our
study setting.
As we expected, the mortality rate was higher in the NEC
group. However, we could unfortunately not show any significant
risk factors for NEC-related mortality.
A limitation of this study is especially the small number
of patients included and the single center retrospective setting.
An imperfect matching of the patients is also a source of
potential bias. Moreover, the case-control design as such
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TABLE 1 | Risk of NEC and of NEC-outcomes.
Variable OR CI95% p-Value
NEC risk factors - univariate model
Suspected sepsis before NEC onset 3.6 1.1–13 0.036
NEC risk factors - multivariate
Platelet count 6.1 1.60–29.96 0.013
Suspected sepsis before NEC onset 5.2 1.39–22.84 0.019
Risk factors for Bell III - univariate model
APGAR 1st minute 0.45 0.18–0.84 0.034
does not allow to identify predictors, but rather correlation
between parameters.
Additionally, since due to internal database limitations we
could not assess the entire number of infants with a PDA or with
a PDA that were scheduled for treatment or who developed NEC
in the period studied, we could not provide details of how often
the respective diseases occurred during the study period.
Nevertheless, we were able to indicate some parameters that
correlated with the development of NEC in patients with PDA
(such as suspected sepsis, CRP level, platelet count). Further
studies, including prospective studies, are needed to clarify this
more thoroughly.
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